Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck

Carcinogenesis

Volumn 30, Issue 12, 2009, Pages 2053-2058

  Niu, Jiangong ^a   Huang, Yu Jing ^a   Wang, Li E ^a   Sturgis, Erich M ^a   Wei, Qingyi ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 13; BIOLOGICAL MARKER; PTPN13 PROTEIN, HUMAN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEAD AND NECK CARCINOMA; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SQUAMOUS CELL CARCINOMA; ADOLESCENT; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; RISK;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 13; RISK;

EID: 73949131745     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp265     Document Type: Article

References (28)

1. Jemal, A. et al. (2009) Cancer statistics, 2009. CA Cancer J. Clin., 59, 225-249.
2. Hsu, T.C. et al. (1991) Mutagen sensitivity: a biological marker of cancer susceptibility. Cancer Epidemiol. Biomarkers Prev., 1, 83-89.
3. Ho, T. et al. (2007) Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck, 29, 682-699.
4. Chen, K. et al. (2007) Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis, 28, 2008-2012.
5. Sturgis, E.M. et al. (2002) DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg., 128, 1084-1088.
6. Zhang, Z. et al. (2006) Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin. Cancer Res., 12, 5596-5602.
7. Chen, K. et al. (2008) CASP3 polymorphisms and risk of squamous cell carcinoma of the head and neck. Clin. Cancer Res., 14, 6343-6349.
8. Gloire, G. et al. (2008) Regulation of CD95/APO-1/Fas-induced apoptosis by protein phosphatases. Biochem. Pharmacol., 76, 1451-1458.
9. Ungefroren, H. et al. (1998) Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res., 58, 1741-1749.
10. Lee, S.H. et al. (2001) Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum. Pathol., 32, 250-256.
11. Yao, H. et al. (2004) Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer. Br. J. Cancer, 91, 1718-1725.
12. Ungefroren, H. et al. (2001) FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. J. Cell Sci., 114, 2735-2746.
13. Eischen, C.M. et al. (1994) Tyrosine kinase activation provides an early and requisite signal for Fas-induced apoptosis. J. Immunol., 153, 1947-1954.
14. Foehr, E.D. et al. (2005) FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS. J. Neurooncol., 74, 241-248.
15. Yanagisawa, J. et al. (1997) The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fasinduced apoptosis. J. Biol. Chem., 272, 8539-8545.
16. Meinhold-Heerlein, I. et al. (2001) Expression and potential role of Fasassociated phosphatase-1 in ovarian cancer. Am. J. Pathol., 158, 1335-1344.
17. Wieckowski, E. et al. (2007) FAP-1-mediated activation of NF-kappaB induces resistance of head and neck cancer to Fas-induced apoptosis. J. Cell Biochem., 100, 16-28.
18. Gastman, B.R. et al. (1999) Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res., 59, 5356-5364.
19. Itakura, M. et al. (2000) Both HPV and carcinogen contribute to the development of resistance to apoptosis during oral carcinogenesis. Int. J. Oncol., 16, 591-597.
20. Mishima, K. et al. (2005) Etodolac, a selective cyclo-oxygenase-2 inhibitor, enhances carboplatin-induced apoptosis of human tongue carcinoma cells by down-regulation of FAP-1 expression. Oral Oncol., 41, 77-81.
21. Yeh, S.H. et al. (2006) Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma. Clin. Cancer Res., 12, 1097-1108.
22. Hong, Y. et al. (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res., 65, 9582-9587.
23. Stephens, M. et al. (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet., 76, 449-462.
24. Stephens, M. et al. (2001) A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet., 68, 978-989.
25. Irie, S. et al. (1999) Functional interaction of Fas-associated phosphatase-1 (FAP-1) with p75(NTR) and their effect on NF-kappaB activation. FEBS Lett., 460, 191-198.
26. Thursz, M.R. et al. (1997) Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat. Genet., 17, 11-12.
27. Jeffery, K.J. et al. (2000) The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J. Immunol., 165, 7278-7284.
28. Carrington, M. et al. (1999) HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science, 283, 1748 1752.